The completion of the GMP facility is a significant milestone for Applied DNA Sciences, as it enables the company to start a new commercialization phase for its LineaRx subsidiary. This development is likely to positively impact the company's stock price in the short term, as it opens up new revenue opportunities. Additionally, the negotiation of a GMP supply agreement suggests potential future partnerships or contracts, further supporting a positive outlook.